RxDoctor Payments Data

Michael Mohr, PA

Physician Assistant · Coeur D Alene, IDNPI 1376694737

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boston Scientific at 38.6% of the total. 2025 is the largest year on record at $233, 2.4 times the $97 reported in 2021.

$832in general payments, 2019–2025

Across 12 payments — averaging $69.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$321
  • Abiomed$153
  • Kestra Medical Technology Services, Inc.$126
  • Pfizer$100
  • Abbott$78
  • Johnson & Johnson$36
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$832 in reported general payments places this provider in the 70th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$44,617
Medicare patients
374
Services billed
615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$106,423
EntrestoSacubitril/Valsartan49$63,984
XareltoRivaroxaban30$49,867
BrilintaTicagrelor44$19,972
JardianceEmpagliflozin15$11,071
FarxigaDapagliflozin Propanediol13$8,261
Metoprolol Succinate163$2,016
Atorvastatin Calcium83$792
ClopidogrelClopidogrel Bisulfate43$678
Losartan Potassium67$565
Potassium Chloride45$493
Rosuvastatin Calcium36$398
Lisinopril47$327
Nitroglycerin28$298
Amlodipine Besylate60$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$100$106,42392 claims
Johnson & JohnsonXarelto$36$49,86730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Coeur D Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →